--- title: "12:26 ETNASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Action" type: "News" locale: "en" url: "https://longbridge.com/en/news/293499740.md" description: "Berger Montague PC announced a securities fraud class action against Erasca, Inc. (NASDAQ: ERAS) for investors who bought stock between Jan 14, 2025, and Apr 26, 2026. The suit alleges the company made deceptive statements about its drug candidate ERAS-0015 while hiding patent disputes. Following disclosures of these issues and a patient death in clinical data on April 27, 2026, Erasca's stock dropped over 45%. Investors have until August 10, 2026, to seek lead plaintiff status." datetime: "2026-07-22T16:26:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293499740.md) - [en](https://longbridge.com/en/news/293499740.md) - [zh-HK](https://longbridge.com/zh-HK/news/293499740.md) --- # 12:26 ETNASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Action , /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against **Erasca, Inc. (NASDAQ: ERAS)** ("Erasca" or the "Company") on behalf of investors who purchased or acquired Erasca common stock during the period from **January 14, 2025 through April 26, 2026** (the "Class Period"). **_Investor Deadline:_** _Investors who purchased or acquired Erasca securities during the Class Period may, no later than_ **_August 10, 2026_**_, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,_ **_CLICK HERE_**_._ Headquartered in San Diego, Calif., Erasca is a clinical-stage precision oncology company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. The Company's lead product candidate, ERAS-0015, is a pan-RAS molecular glue in development for the treatment of patients with RAS-mutated solid tumors. According to the complaint, throughout the Class Period, Defendants made repeatedly positive public statements touting ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper and exposed the Company to patent and trade secret disputes. The truth allegedly began to emerge on April 27, 2026, when Erasca disclosed that Revolution Medicines had accused the Company of patent infringement and trade secret misappropriation, and that Erasca had made deceptive comparative statements regarding ERAS-0015. Later that day, Erasca reported preliminary clinical data that included a patient death and acknowledged that comparisons between ERAS-0015 and competing therapies were based on inherently limited cross-study analyses rather than head-to-head clinical trials. Following these disclosures, Erasca's stock price fell more than **45%**, or $9.90 per share. **_If you are an Erasca investor and would like to learn more about this action,_** **_CLICK HERE_** **_or please contact Berger Montague: Andrew Abramowitz at_** **_\[email protected\]_** **_or (215) 875-3015, or Caitlin Adorni at_** **_\[email protected\]_** **_or (267) 764-4865._** **About Berger Montague** Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. For more information or to discuss your rights, please contact: **Andrew Abramowitz **Berger Montague (215) 875-3015 aabramowitz@bergermontague.com** Caitlin Adorni **Berger Montague (267) 764-4865 \[email protected\] SOURCE Berger Montague ### Related Stocks - [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md) - [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md) - [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md) ## Related News & Research - [Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt](https://longbridge.com/en/news/293631868.md) - [15:31 ETErasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/293790753.md) - [Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/293183481.md) - [16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS](https://longbridge.com/en/news/293383085.md) - [Fifth Era Acquisition Corp I (NASDAQ:FERA) Short Interest Down 71.1% in July](https://longbridge.com/en/news/293844836.md)